首页 > 最新文献

Interventional Cardiology Review最新文献

英文 中文
Haemodynamic Interplay Between Concomitant Left Ventricular Outflow Tract Obstruction and Aortic Stenosis. 伴发左室流出道阻塞与主动脉狭窄的血流动力学相互作用。
0 PHILOSOPHY Pub Date : 2021-06-10 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2020.36
Priya Bansal, Hamza Lodhi, Adithya Mathews, Anand Desai, Ramez Morcos, Brijeshwar Maini, Houman Khalili

The authors describe a patient with hypertrophic cardiomyopathy with concomitant left ventricular outflow tract obstruction and aortic stenosis. Detailed haemodynamic assessment of the serial lesions was performed. Alcohol septal ablation resulted in a significant reduction of gradients across the left ventricular outflow tract.

作者描述了一例伴有左心室流出道梗阻和主动脉狭窄的肥厚性心肌病患者。对一系列病变进行了详细的血流动力学评估。酒精性室间隔消融术导致左心室流出道梯度显著降低。
{"title":"Haemodynamic Interplay Between Concomitant Left Ventricular Outflow Tract Obstruction and Aortic Stenosis.","authors":"Priya Bansal,&nbsp;Hamza Lodhi,&nbsp;Adithya Mathews,&nbsp;Anand Desai,&nbsp;Ramez Morcos,&nbsp;Brijeshwar Maini,&nbsp;Houman Khalili","doi":"10.15420/icr.2020.36","DOIUrl":"https://doi.org/10.15420/icr.2020.36","url":null,"abstract":"<p><p>The authors describe a patient with hypertrophic cardiomyopathy with concomitant left ventricular outflow tract obstruction and aortic stenosis. Detailed haemodynamic assessment of the serial lesions was performed. Alcohol septal ablation resulted in a significant reduction of gradients across the left ventricular outflow tract.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e11"},"PeriodicalIF":0.0,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/e7/icr-16-e11.PMC8239956.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39045248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
What an Interventionalist Needs to Know About MI with Non-obstructive Coronary Arteries. 介入医师需要了解的非阻塞性冠状动脉心肌梗死知识。
0 PHILOSOPHY Pub Date : 2021-06-10 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2021.10
Robert Sykes, Daniel Doherty, Kenneth Mangion, Andrew Morrow, Colin Berry

MI with non-obstructive coronary arteries (MINOCA) is caused by a heterogeneous group of vascular or myocardial disorders. MINOCA occurs in 5.15% of patients presenting with acute ST-segment elevation MI or non-ST segment elevation MI and prognosis is impaired. The diagnosis of MINOCA is made during coronary angiography following acute MI, where there is no stenosis ≥50% present in an infarct-related epicardial artery and no overt systemic aetiology for the presentation. Accurate diagnosis and subsequent management require the appropriate utilisation of intravascular imaging, coronary function testing and subsequent imaging to assess for myocardial disorders without coronary involvement. Although plaque-related MINOCA is currently managed with empirical secondary prevention strategies, there remains an unmet therapeutic need for targeted and evidence-based therapy for MINOCA patients and increased awareness of the recommended diagnostic pathway.

冠状动脉非阻塞性心肌梗死(MINOCA)是由一组不同的血管或心肌疾病引起的。在急性 ST 段抬高型心肌梗死或非 ST 段抬高型心肌梗死患者中,5.15% 的患者会出现 MINOCA,且预后不良。MINOCA 的诊断是在急性心肌梗死后进行冠状动脉造影时做出的,此时梗死相关的心外膜动脉无≥50% 的狭窄,且无明显的全身病因。准确诊断和后续治疗需要适当利用血管内成像、冠状动脉功能测试和后续成像来评估未累及冠状动脉的心肌疾病。尽管斑块相关的 MINOCA 目前可通过经验性二级预防策略进行管理,但 MINOCA 患者的针对性循证治疗需求仍未得到满足,而且人们对推荐诊断途径的认识也有待提高。
{"title":"What an Interventionalist Needs to Know About MI with Non-obstructive Coronary Arteries.","authors":"Robert Sykes, Daniel Doherty, Kenneth Mangion, Andrew Morrow, Colin Berry","doi":"10.15420/icr.2021.10","DOIUrl":"10.15420/icr.2021.10","url":null,"abstract":"<p><p>MI with non-obstructive coronary arteries (MINOCA) is caused by a heterogeneous group of vascular or myocardial disorders. MINOCA occurs in 5.15% of patients presenting with acute ST-segment elevation MI or non-ST segment elevation MI and prognosis is impaired. The diagnosis of MINOCA is made during coronary angiography following acute MI, where there is no stenosis ≥50% present in an infarct-related epicardial artery and no overt systemic aetiology for the presentation. Accurate diagnosis and subsequent management require the appropriate utilisation of intravascular imaging, coronary function testing and subsequent imaging to assess for myocardial disorders without coronary involvement. Although plaque-related MINOCA is currently managed with empirical secondary prevention strategies, there remains an unmet therapeutic need for targeted and evidence-based therapy for MINOCA patients and increased awareness of the recommended diagnostic pathway.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e10"},"PeriodicalIF":0.0,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/db/icr-16-e10.PMC8218171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39142805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Moderate Aortic Stenosis: What is it and When Should We Intervene? 中度主动脉瓣狭窄:什么是中度主动脉瓣狭窄,什么时候应该干预?
0 PHILOSOPHY Pub Date : 2021-05-27 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2021.04
Sveeta Badiani, Sanjeev Bhattacharyya, Nikoo Aziminia, Thomas A Treibel, Guy Lloyd

Current guidelines recommend aortic valve replacement in patients with severe aortic stenosis in the presence of symptoms or a left ventricular ejection fraction <50%. However, patients with less than severe aortic stenosis may also experience symptoms and recent literature suggests that the prognosis is not as benign as previously reported. There are no recommendations for patients with moderate aortic stenosis and left ventricular dysfunction, despite the high associated morbidity and mortality. There is also some evidence that these patients may benefit from early aortic valve intervention. It is recognised that aortic stenosis not only affects the valve but also has a complex myocardial response. This review discusses the natural history of moderate aortic stenosis along with the role of multimodality imaging in risk stratification in these patients.

目前的指南建议在出现症状或左心室射血分数较高的严重主动脉瓣狭窄患者行主动脉瓣置换术
{"title":"Moderate Aortic Stenosis: What is it and When Should We Intervene?","authors":"Sveeta Badiani,&nbsp;Sanjeev Bhattacharyya,&nbsp;Nikoo Aziminia,&nbsp;Thomas A Treibel,&nbsp;Guy Lloyd","doi":"10.15420/icr.2021.04","DOIUrl":"https://doi.org/10.15420/icr.2021.04","url":null,"abstract":"<p><p>Current guidelines recommend aortic valve replacement in patients with severe aortic stenosis in the presence of symptoms or a left ventricular ejection fraction <50%. However, patients with less than severe aortic stenosis may also experience symptoms and recent literature suggests that the prognosis is not as benign as previously reported. There are no recommendations for patients with moderate aortic stenosis and left ventricular dysfunction, despite the high associated morbidity and mortality. There is also some evidence that these patients may benefit from early aortic valve intervention. It is recognised that aortic stenosis not only affects the valve but also has a complex myocardial response. This review discusses the natural history of moderate aortic stenosis along with the role of multimodality imaging in risk stratification in these patients.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e09"},"PeriodicalIF":0.0,"publicationDate":"2021-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/cf/icr-16-e09.PMC8201468.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39142804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Minimally Invasive Coronary Revascularisation Surgery: A Focused Review of the Available Literature. 微创冠状动脉血管重建术:对现有文献的重点回顾。
0 PHILOSOPHY Pub Date : 2021-05-19 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2021.05
Karel M Van Praet, Markus Kofler, Timo Z Nazari Shafti, Alaa Abd El Al, Antonia van Kampen, Andrea Amabile, Gianluca Torregrossa, Jörg Kempfert, Volkmar Falk, Husam H Balkhy, Stephan Jacobs

Minimally invasive coronary revascularisation was originally developed in the mid 1990s as minimally invasive direct coronary artery bypass (MIDCAB) grafting is a less invasive approach compared to conventional coronary artery bypass grafting (CABG) to address targets in the left anterior descending coronary artery (LAD). Since then, MIDCAB has evolved with the adoption of a robotic platform and the possibility to perform multivessel bypass procedures. Minimally invasive coronary revascularisation surgery also allows for a combination between the benefits of CABG and percutaneous coronary interventions for non-LAD lesions - a hybrid approach. Hybrid coronary revascularisation results in fewer blood transfusions, shorter hospital stay, decreased ventilation times and patients return to work sooner when compared to conventional CABG. This article reviews the available literature, describes standard approaches and considers topics, such as limited access procedures, indications and patient selection, diagnostics and imaging, techniques, anastomotic devices, hybrid coronary revascularisation and outcome analysis.

微创冠状动脉血管重建术最初是在20世纪90年代中期发展起来的,因为与传统冠状动脉旁路移植术(CABG)相比,微创直接冠状动脉旁路移植术(MIDCAB)是一种侵入性更小的方法,可以解决冠状动脉左前降支(LAD)的目标。从那时起,MIDCAB随着机器人平台的采用和多血管旁路手术的可能性而不断发展。微创冠状动脉血管重建术也可以结合冠状动脉搭桥和经皮冠状动脉介入治疗非lad病变的优点——一种混合方法。与传统冠状动脉搭桥相比,混合型冠状动脉重建术可减少输血量、缩短住院时间、减少通气时间和患者更快重返工作岗位。本文回顾了现有的文献,描述了标准方法,并考虑了一些主题,如有限的准入程序,适应症和患者选择,诊断和成像,技术,吻合装置,混合冠状动脉重建术和结果分析。
{"title":"Minimally Invasive Coronary Revascularisation Surgery: A Focused Review of the Available Literature.","authors":"Karel M Van Praet,&nbsp;Markus Kofler,&nbsp;Timo Z Nazari Shafti,&nbsp;Alaa Abd El Al,&nbsp;Antonia van Kampen,&nbsp;Andrea Amabile,&nbsp;Gianluca Torregrossa,&nbsp;Jörg Kempfert,&nbsp;Volkmar Falk,&nbsp;Husam H Balkhy,&nbsp;Stephan Jacobs","doi":"10.15420/icr.2021.05","DOIUrl":"https://doi.org/10.15420/icr.2021.05","url":null,"abstract":"<p><p>Minimally invasive coronary revascularisation was originally developed in the mid 1990s as minimally invasive direct coronary artery bypass (MIDCAB) grafting is a less invasive approach compared to conventional coronary artery bypass grafting (CABG) to address targets in the left anterior descending coronary artery (LAD). Since then, MIDCAB has evolved with the adoption of a robotic platform and the possibility to perform multivessel bypass procedures. Minimally invasive coronary revascularisation surgery also allows for a combination between the benefits of CABG and percutaneous coronary interventions for non-LAD lesions - a hybrid approach. Hybrid coronary revascularisation results in fewer blood transfusions, shorter hospital stay, decreased ventilation times and patients return to work sooner when compared to conventional CABG. This article reviews the available literature, describes standard approaches and considers topics, such as limited access procedures, indications and patient selection, diagnostics and imaging, techniques, anastomotic devices, hybrid coronary revascularisation and outcome analysis.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e08"},"PeriodicalIF":0.0,"publicationDate":"2021-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/69/icr-16-e08.PMC8287382.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39210890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Transcatheter Mitral Valve Replacement: Current Evidence and Concepts. 经导管二尖瓣置换术:目前的证据和概念。
0 PHILOSOPHY Pub Date : 2021-05-01 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2020.25
Ozan M Demir, Mhairi Bolland, Jonathan Curio, Lars Søndergaard, Josep Rodés-Cabau, Simon Redwood, Bernard Prendergast, Antonio Colombo, Mei Chau, Azeem Latib

Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.

在过去的十年中,已经开发了几种经导管装置来解决高手术风险患者严重二尖瓣反流(MR)的治疗,主要旨在修复天然二尖瓣(MV)。近年来,中压修复装置已被证明具有较高的疗效和安全性。然而,为了复制有希望的试验结果,必须满足特定的解剖和病理生理标准,操作人员需要高水平的经验。到目前为止,经导管中压修复的长期耐久性仍然未知。经导管MV置换术(TMVR)可能是一种治疗选择,能够针对各种解剖结构,可靠地消除MR,并通过标准化的植入方案促进易用性。本文综述了即将推出的TMVR设备和现有数据,并讨论了TMVR如何进一步推进经导管治疗MR领域。
{"title":"Transcatheter Mitral Valve Replacement: Current Evidence and Concepts.","authors":"Ozan M Demir,&nbsp;Mhairi Bolland,&nbsp;Jonathan Curio,&nbsp;Lars Søndergaard,&nbsp;Josep Rodés-Cabau,&nbsp;Simon Redwood,&nbsp;Bernard Prendergast,&nbsp;Antonio Colombo,&nbsp;Mei Chau,&nbsp;Azeem Latib","doi":"10.15420/icr.2020.25","DOIUrl":"https://doi.org/10.15420/icr.2020.25","url":null,"abstract":"<p><p>Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e07"},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/25/icr-16-e07.PMC8135015.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38936878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Contemporary Management of Isolated Ostial Side Branch Disease: An Evidence-based Approach to Medina 001 Bifurcations. 孤立口侧分支疾病的当代管理:以证据为基础的Medina 001分支方法。
0 PHILOSOPHY Pub Date : 2021-04-05 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2020.30
Suleiman Suleiman, J J Coughlan, George Touma, Richard Szirt

The optimal management of bifurcation lesions has received significant interest in recent years and remains a matter of debate among the interventional cardiology community. Bifurcation lesions are encountered in approximately 21% of percutaneous coronary intervention procedures and are associated with an increased risk of major adverse cardiac events. The Medina classification has been developed in an attempt to standardise the terminology when describing bifurcation lesions. The focus of this article is on the management of the Medina 0,0,1 lesion ('Medina 001'), an uncommon lesion encountered in <5% of all bifurcations. Technical considerations, management options and interventional techniques relating to the Medina 001 lesion are discussed. In addition, current published data supporting the various proposed interventional treatment strategies are examined in an attempt to delineate an evidence-based approach to this uncommon lesion.

分叉病变的最佳管理近年来受到了极大的关注,并且在介入性心脏病学界仍然存在争议。大约21%的经皮冠状动脉介入手术会遇到分叉病变,并且与主要心脏不良事件的风险增加有关。麦地那分类是为了在描述分岔病变时标准化术语而发展起来的。本文的重点是麦地那0,0,1病变(“麦地那001”)的处理,这是一种罕见的病变
{"title":"Contemporary Management of Isolated Ostial Side Branch Disease: An Evidence-based Approach to Medina 001 Bifurcations.","authors":"Suleiman Suleiman,&nbsp;J J Coughlan,&nbsp;George Touma,&nbsp;Richard Szirt","doi":"10.15420/icr.2020.30","DOIUrl":"https://doi.org/10.15420/icr.2020.30","url":null,"abstract":"<p><p>The optimal management of bifurcation lesions has received significant interest in recent years and remains a matter of debate among the interventional cardiology community. Bifurcation lesions are encountered in approximately 21% of percutaneous coronary intervention procedures and are associated with an increased risk of major adverse cardiac events. The Medina classification has been developed in an attempt to standardise the terminology when describing bifurcation lesions. The focus of this article is on the management of the Medina 0,0,1 lesion ('Medina 001'), an uncommon lesion encountered in <5% of all bifurcations. Technical considerations, management options and interventional techniques relating to the Medina 001 lesion are discussed. In addition, current published data supporting the various proposed interventional treatment strategies are examined in an attempt to delineate an evidence-based approach to this uncommon lesion.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e06"},"PeriodicalIF":0.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/55/15/icr-16-e06.PMC8054348.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38906984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Frailty Scores and Their Utility in Older Patients with Cardiovascular Disease. 衰弱评分及其在老年心血管疾病患者中的应用
0 PHILOSOPHY Pub Date : 2021-03-31 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2020.18
Kenneth Jordan Ng Cheong Chung, Chris Wilkinson, Murugapathy Veerasamy, Vijay Kunadian

The world's population is ageing, resulting in more people with frailty receiving treatment for cardiovascular disease (CVD). The emergence of novel interventions, such as transcatheter aortic valve implantation, has also increased the proportion of older patients being treated in later stages of life. This increasing population burden makes the assessment of frailty of utmost importance, especially in patients with CVD. Despite a growing body of evidence on the association between frailty and CVD, there is no consensus on the optimal frailty assessment tool for use in clinical settings. Previous studies have shown limited concordance between validated frailty instruments. This review evaluates the evidence on the utility of frailty assessment tools in patients with CVD, and the effect of frailty on different outcomes measured.

世界人口正在老龄化,导致更多体弱多病的人接受心血管疾病治疗。新的干预措施的出现,如经导管主动脉瓣植入术,也增加了老年患者在生命后期接受治疗的比例。这种不断增加的人口负担使得脆弱性评估变得至关重要,特别是在心血管疾病患者中。尽管越来越多的证据表明虚弱和心血管疾病之间存在关联,但对于临床使用的最佳虚弱评估工具尚无共识。先前的研究表明,在经过验证的虚弱仪器之间存在有限的一致性。这篇综述评估了衰弱评估工具在心血管疾病患者中的效用的证据,以及衰弱对不同结果的影响。
{"title":"Frailty Scores and Their Utility in Older Patients with Cardiovascular Disease.","authors":"Kenneth Jordan Ng Cheong Chung,&nbsp;Chris Wilkinson,&nbsp;Murugapathy Veerasamy,&nbsp;Vijay Kunadian","doi":"10.15420/icr.2020.18","DOIUrl":"https://doi.org/10.15420/icr.2020.18","url":null,"abstract":"<p><p>The world's population is ageing, resulting in more people with frailty receiving treatment for cardiovascular disease (CVD). The emergence of novel interventions, such as transcatheter aortic valve implantation, has also increased the proportion of older patients being treated in later stages of life. This increasing population burden makes the assessment of frailty of utmost importance, especially in patients with CVD. Despite a growing body of evidence on the association between frailty and CVD, there is no consensus on the optimal frailty assessment tool for use in clinical settings. Previous studies have shown limited concordance between validated frailty instruments. This review evaluates the evidence on the utility of frailty assessment tools in patients with CVD, and the effect of frailty on different outcomes measured.</p>","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e05"},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/73/cf/icr-16-e05.PMC8054346.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38906983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 26
Extended Statement by the British Cardiovascular Intervention Society President Regarding Transcatheter Aortic Valve Implantation. 英国心血管介入学会会长关于经导管主动脉瓣植入术的扩展声明。
0 PHILOSOPHY Pub Date : 2021-03-25 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2021.02
Philip MacCarthy, Dave Smith, Douglas Muir, Daniel Blackman, Mamta Buch, Peter Ludman, Clare Appleby, Nick Curzen, David Hildick-Smith, Neal Uren, Mark Turner, Uday Trivedi, Adrian Banning
© RADCLIFFE CARDIOLOGY 2021 Access at: www.ICRjournal.com Transcatheter aortic valve implantation (TAVI) has now become the default intervention for severe, symptomatic aortic stenosis (AS) in inoperable and high-risk patients and patients at intermediate risk who are anatomically suitable for the transfemoral approach, under the guidance of a multidisciplinary heart team. Evidence is building for the use of TAVI in low-risk patients and as a result, the number of TAVI procedures in all developed nations is increasing dramatically. The number of TAVI procedures exceeded the number of isolated surgical aortic valve replacements in the US in 2015 and all surgical aortic valve replacements in 2018 according to the latest Transcatheter Valve Therapy Registry data.1 Although the UK is lagging behind most of these nations, the numbers of TAVI procedures is nevertheless increasing year by year.
{"title":"Extended Statement by the British Cardiovascular Intervention Society President Regarding Transcatheter Aortic Valve Implantation.","authors":"Philip MacCarthy,&nbsp;Dave Smith,&nbsp;Douglas Muir,&nbsp;Daniel Blackman,&nbsp;Mamta Buch,&nbsp;Peter Ludman,&nbsp;Clare Appleby,&nbsp;Nick Curzen,&nbsp;David Hildick-Smith,&nbsp;Neal Uren,&nbsp;Mark Turner,&nbsp;Uday Trivedi,&nbsp;Adrian Banning","doi":"10.15420/icr.2021.02","DOIUrl":"https://doi.org/10.15420/icr.2021.02","url":null,"abstract":"© RADCLIFFE CARDIOLOGY 2021 Access at: www.ICRjournal.com Transcatheter aortic valve implantation (TAVI) has now become the default intervention for severe, symptomatic aortic stenosis (AS) in inoperable and high-risk patients and patients at intermediate risk who are anatomically suitable for the transfemoral approach, under the guidance of a multidisciplinary heart team. Evidence is building for the use of TAVI in low-risk patients and as a result, the number of TAVI procedures in all developed nations is increasing dramatically. The number of TAVI procedures exceeded the number of isolated surgical aortic valve replacements in the US in 2015 and all surgical aortic valve replacements in 2018 according to the latest Transcatheter Valve Therapy Registry data.1 Although the UK is lagging behind most of these nations, the numbers of TAVI procedures is nevertheless increasing year by year.","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e03"},"PeriodicalIF":0.0,"publicationDate":"2021-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/48/icr-16-e03.PMC8054375.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38906981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Shifting Paradigms and Financing a Revolution: Providing Transcatheter Valves in the Public Health System. A View from Aotearoa New Zealand. 转变模式和为革命融资:在公共卫生系统中提供经导管瓣膜。从新西兰奥特罗亚眺望。
0 PHILOSOPHY Pub Date : 2021-03-25 eCollection Date: 2021-04-01 DOI: 10.15420/icr.2020.03
Cameron McAlister, David Smyth
In The Structure of Scientific Revolutions, Thomas Kuhn, the American philosopher of science, argued that scientific advances occur by revolution when the dominant scientific theory of the day is lacking and is rapidly replaced by a new radical theory.1 For example, the European voyages to the Americas in the 15th and 16th centuries required accurate navigation. The prevalent geocentric view at the time, that the celestial bodies circled the Earth, was woefully inaccurate as a basis for transatlantic navigation. Accordingly, the geocentric view was overthrown and rapidly superseded by the heliocentric view put forward by Copernicus, which provided much more accurate navigation. There was, to use Kuhn’s terminology, a paradigm shift. As with all revolutions, there were casualties. The imprisonment of Galileo is well known, but Michael Servetus (who is credited with describing pulmonary circulation before William Harvey) was burned at the stake under Calvin’s orders, partly for embracing this idea. The recent trials in transcatheter aortic valve implantation (TAVI) have resulted in a paradigm shift away from surgical aortic valve replacement (sAVR) as the gold standard definitive therapy in the treatment of aortic stenosis.2–8 It seems that a revolution is underway in the treatment of aortic stenosis, but hopefully without imprisonments or burnings.
{"title":"Shifting Paradigms and Financing a Revolution: Providing Transcatheter Valves in the Public Health System. A View from Aotearoa New Zealand.","authors":"Cameron McAlister,&nbsp;David Smyth","doi":"10.15420/icr.2020.03","DOIUrl":"https://doi.org/10.15420/icr.2020.03","url":null,"abstract":"In The Structure of Scientific Revolutions, Thomas Kuhn, the American philosopher of science, argued that scientific advances occur by revolution when the dominant scientific theory of the day is lacking and is rapidly replaced by a new radical theory.1 For example, the European voyages to the Americas in the 15th and 16th centuries required accurate navigation. The prevalent geocentric view at the time, that the celestial bodies circled the Earth, was woefully inaccurate as a basis for transatlantic navigation. Accordingly, the geocentric view was overthrown and rapidly superseded by the heliocentric view put forward by Copernicus, which provided much more accurate navigation. There was, to use Kuhn’s terminology, a paradigm shift. As with all revolutions, there were casualties. The imprisonment of Galileo is well known, but Michael Servetus (who is credited with describing pulmonary circulation before William Harvey) was burned at the stake under Calvin’s orders, partly for embracing this idea. The recent trials in transcatheter aortic valve implantation (TAVI) have resulted in a paradigm shift away from surgical aortic valve replacement (sAVR) as the gold standard definitive therapy in the treatment of aortic stenosis.2–8 It seems that a revolution is underway in the treatment of aortic stenosis, but hopefully without imprisonments or burnings.","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 ","pages":"e04"},"PeriodicalIF":0.0,"publicationDate":"2021-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/e0/icr-16-e04.PMC8054347.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38906982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Cardiac Unloading and Recovery: Proceedings of the 5th Annual Acute Cardiac Unloading and REcovery (A-CURE) symposium held on 14 December 2020. 急性心脏负荷与恢复:2020年12月14日举行的第五届急性心脏负荷与恢复(A-CURE)年度研讨会论文集。
IF 0.2 0 PHILOSOPHY Pub Date : 2021-03-23 eCollection Date: 2021-03-01 DOI: 10.15420/icr.2021.S2
{"title":"Acute Cardiac Unloading and Recovery: Proceedings of the 5th Annual Acute Cardiac Unloading and REcovery (A-CURE) symposium held on 14 December 2020.","authors":"","doi":"10.15420/icr.2021.S2","DOIUrl":"10.15420/icr.2021.S2","url":null,"abstract":"","PeriodicalId":38586,"journal":{"name":"Interventional Cardiology Review","volume":"16 Suppl 2","pages":"1-3"},"PeriodicalIF":0.2,"publicationDate":"2021-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108564/pdf/icr-16-Suppl2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38898369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Interventional Cardiology Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1